Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 20/20 | 1.00 |
| ▸ | SLC5A1 | P13866 | 18/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2252696 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1 | |
| SCHEMBL2254615 | 0.93 | SLC5A2 (1.00) | SLC5A2SLC5A1 | |
| SCHEMBL2257487 | 0.92 | SLC5A2 (1.00) | SLC5A2SLC5A1 | |
| SCHEMBL2257293 | 0.90 | SLC5A2 (1.00) | SLC5A2SLC5A1 | |
| SCHEMBL2253777 | 0.90 | SLC5A2 (1.00) | SLC5A2SLC5A1 | |
| SCHEMBL2252419 | 0.90 | SLC5A2 (1.00) | SLC5A2SLC5A1 | |
| SCHEMBL2253329 | 0.89 | SLC5A2 (0.82) | SLC5A2SLC5A1 | |
| SCHEMBL2257518 | 0.89 | SLC5A2 (0.82) | SLC5A2SLC5A1 | |
| SCHEMBL4356601 | 0.89 | SLC5A2 (0.81) | SLC5A2SLC5A1 | |
| SCHEMBL4664945 | 0.89 | SLC5A2 (0.81) | SLC5A2SLC5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020242537-A1 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISEASE | AVOLYNT (US) | 2020-12-03 | — | — | WO | disclosed |
| US-7989424-B2 | Glucopyranosyloxypyrazole derivatives and use thereof in medicines | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2011-08-02 | — | — | US | disclosed |
| US-20090093419-A1 | GLUCOPYRANOSYLOXYPYRAZOLE DERIVATIVES AND USE THEREOF IN MEDICINES | KISSEI PHARMACEUTICAL CO. LTD. (JP) | 2009-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093419-A1 | GLUCOPYRANOSYLOXYPYRAZOLE DERIVATIVES AND USE THEREOF IN MEDICINES | SLC5A2, SLC5A1, SLC2A4 | SLC5A2 1/4885SLC5A1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.